← Back to Clinical Trials
Recruiting Phase 3 NCT04217512

Pantoprazole in Cisplatin Nephrotoxicity

Trial Parameters

Condition Oncology
Sponsor Sherief Abd-Elsalam
Study Type INTERVENTIONAL
Phase Phase 3
Enrollment 60
Sex ALL
Min Age N/A
Max Age N/A
Start Date 2019-05-01
Completion 2030-12-01
Interventions
Pantoprazole low dosePantoprazole high doseStandard hydration

Brief Summary

Pantoprazole in Cisplatin Nephrotoxicity

Eligibility Criteria

Inclusion Criteria: * Patients with head and neck cancer Exclusion Criteria: * GFR less than 59. * DM * Elevated liver enzymes more than 3 fold.

Related Trials